Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra.
Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra. Stem-cell research pursues two complementary routes: neurogenic cells differentiated toward dopamine neurons are studied to replace lost cells and restore dopamine signalling, while placental mesenchymal stem cells are explored for neuroprotection — slowing degeneration through anti-inflammatory and growth-factor secretion. Preclinical evidence suggests dopamine-releasing cells can reinnervate the striatum and that trophic factors may delay neuronal death. Key challenges are achieving cell survival, integration and functional restoration in a degenerating brain. Most trials are early-phase, with modest motor changes reported.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €3,348–€32,200 (zenifybkk.com, cellmedicine.com) |
| Principalele tipuri de celule studiate | Neurogenic Cells, MSCs from Amniotic Membrane |
| Statutul aprobării | Investigațional |
| Studii înregistrate (ClinicalTrials.gov) | 69 · 16 recruiting now |
For the clinic's own description, see how Stem Plus describes its Parkinson's Disease programme ↗.
Sixty-nine registered trials and 16 recruiting studies investigate stem-cell approaches in Parkinson's. Small series document modest motor-symptom changes within 6–12 months, but are typically unblinded, single-arm, and lack sham controls. A few report dopamine-replacement activity on PET imaging; durability beyond 12 months is sparse. Heterogeneous cell products and delivery routes complicate interpretation. No trial has prevented progression or restored motor function to pre-disease levels.
Depending on assessment, a Parkinson's Disease protocol may draw on:
Indicative European costs are roughly €4,000–€7,000 per infusion. If intracerebral delivery is used, stereotactic neurosurgery, imaging and intensive monitoring can double or triple the total. Some protocols use multiple infusions over months. For context, medical management runs €200–€1,000 monthly and deep-brain stimulation is a large one-time cost — the stem-cell figure is indicative and unproven.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Parkinson's Disease cost-by-country breakdown, or compare the best countries for Parkinson's Disease →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Parkinson's Disease.
FAQ complet Boala Parkinson → · Defalcare costuri Boala Parkinson →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită